Wat is de prijs voor Artiva Biotherapeutics, Inc. (ARTV)

Het prijs van Artiva Biotherapeutics, Inc. (ARTV) is $11.09

Wat is de marktkapitalisatie voor Artiva Biotherapeutics, Inc. (ARTV)

Marktkapitalisatie voorArtiva Biotherapeutics, Inc. (ARTV) is $542.19M

Artiva Biotherapeutics, Inc. (ARTV) WPA

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Jaar	EPS	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

EPS

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	EPS	EPS-verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$-5.29	-	AU
Moderna, Inc. MRNA.US	$-7.98	-	US
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

EPS

EPS-verschil

Land